Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.

This is written in the approval document as:

Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer

Reimbursement

CDS

Citation

Exemestane Monotherapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6568/376_Exemestane_therapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	ER positive, PR positive	Invasive Breast Carcinoma	Exemestane
HSE (1)	ER positive	Invasive Breast Carcinoma	Exemestane
HSE (1)	PR positive	Invasive Breast Carcinoma	Exemestane

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-11-11	Health Service Executive	Indication approved for reimbursement.